Literature DB >> 14625942

The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?

Sandra Nocera1, Dario Bonato, Harry Telser.   

Abstract

The present work focuses on the choice of the elicitation technique within a contingent valuation (CV) framework. We simultaneously apply three different elicitation techniques to elicit willingness-to-pay (WTP) values for three programs against Alzheimer's disease. First, the dichotomous choice approach is used, which is the standard procedure. However, giving respondents only a yes/no response alternative seems to result in overestimated WTP values. Therefore, we secondly apply the dissonance-minimizing format which screens respondents for their preferences and thus avoids possible yea-saying and protest answers against the payment vehicle. The third format, a modified version of the payment card, allows respondents to express a level of voting certainty and to make less of a commitment. With our findings we show that a well-designed CV method is a suitable instrument for helping decision makers in the health care sector and that the Swiss population favors highly a program which improves the situation of informal caregivers.

Entities:  

Mesh:

Year:  2002        PMID: 14625942     DOI: 10.1023/a:1020441726964

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  14 in total

Review 1.  The contingent valuation method in health care.

Authors:  T Klose
Journal:  Health Policy       Date:  1999-05       Impact factor: 2.980

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Theory and methods of economic evaluation of health care.

Authors:  M Johannesson
Journal:  Dev Health Econ Public Policy       Date:  1996

Review 4.  Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

Authors:  G W Small; P V Rabins; P P Barry; N S Buckholtz; S T DeKosky; S H Ferris; S I Finkel; L P Gwyther; Z S Khachaturian; B D Lebowitz; T D McRae; J C Morris; F Oakley; L S Schneider; J E Streim; T Sunderland; L A Teri; L E Tune
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

5.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

6.  Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

Authors:  E Souêtre; R M Thwaites; H L Yeardley
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

7.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

Review 8.  Economic research on Alzheimer disease: a review of the literature.

Authors:  R L Ernst; J W Hay
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

9.  Age-specific incidence of Alzheimer's disease in a community population.

Authors:  L E Hebert; P A Scherr; L A Beckett; M S Albert; D M Pilgrim; M J Chown; H H Funkenstein; D A Evans
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

10.  Documentation and evaluation of cognitive impairment in elderly primary care patients.

Authors:  C M Callahan; H C Hendrie; W M Tierney
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

View more
  6 in total

1.  Validity and Reliability of Willingness-to-Pay Estimates: Evidence from Two Overlapping Discrete-Choice Experiments.

Authors:  Harry Telser; Karolin Becker; Peter Zweifel
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

2.  The general public's willingness to pay for tax increases to support unrestricted access to an Alzheimer's disease medication.

Authors:  Mark Oremus; Jean-Eric Tarride; Parminder Raina; Lehana Thabane; Gary Foster; Charlie H Goldsmith; Natasha Clayton
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

3.  Willingness to pay for adverse drug event regulatory actions.

Authors:  Jacoline Bouvy; Just Weemers; Huub Schellekens; Marc Koopmanschap
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Willingness to Pay for Community-Based Health Insurance Scheme and Associated Factors Among Rural Communities in Gemmachis District, Eastern Ethiopia.

Authors:  Abishu Kado; Bedasa Taye Merga; Hassen Abdi Adem; Yadeta Dessie; Biftu Geda
Journal:  Clinicoecon Outcomes Res       Date:  2020-10-23

5.  Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada.

Authors:  Mark Oremus; Jean-Eric Tarride; Natasha Clayton; Parminder Raina
Journal:  BMC Health Serv Res       Date:  2009-12-29       Impact factor: 2.655

6.  Valuing human leptospirosis prevention using the opportunity cost of labor.

Authors:  Joseph Arbiol; Maridel Borja; Mitsuyasu Yabe; Hisako Nomura; Nina Gloriani; Shin-ichi Yoshida
Journal:  Int J Environ Res Public Health       Date:  2013-05-03       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.